Olema Pharmaceuticals, Inc. OLMA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $176.31M+40.8% | $157.7M+26.6% | $146.78M+24.3% | $140.05M+34.3% | $125.26M+34.4% | ||
| $25.51M+45.5% | $21M+18.4% | $18.61M+4.4% | $17.08M-1.4% | $17.53M+6.3% | ||
| $201.81M+41.3% | $178.7M+25.6% | $165.38M+21.7% | $157.13M+29.2% | $142.79M+30.2% | ||
| -$201.81M-41.3% | -$178.7M-25.6% | -$165.38M-21.7% | -$157.13M-29.2% | -$142.79M-30.2% | ||
| $16.66M+19.9% | $16.25M+27.1% | $15.43M+16.6% | $14.83M+23.6% | $13.9M+34.2% | ||
| -$185.15M-43.6% | -$162.45M-25.5% | -$149.96M-22.2% | -$142.3M-29.8% | -$128.89M-29.8% | ||
| -$2.03-6.8% | -$1.87+11.0% | -$1.76+19.3% | -$1.87+9.2% | -$1.90+5.5% | ||
| -$201.33M-41.4% | -$178.21M-25.6% | -$164.96M-21.7% | -$156.66M-29.2% | -$142.36M-30.2% | ||
| -$201.81M-41.3% | -$178.7M-25.6% | -$165.38M-21.7% | -$157.13M-29.2% | -$142.79M-30.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Olema Pharmaceuticals, Inc. profitable?
- Olema Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $185.2M over the trailing twelve months.
- What is Olema Pharmaceuticals, Inc.'s earnings per share?
- Olema Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.03.
- Where does Olema Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Olema Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.